Additive interaction of levetiracetam with lamotrigine in the mouse 6 Hz psychomotor seizure model-an isobolographic analysis

Current Issues in Pharmacy and Medical Sciences

Volumn 26, Issue 1, 2013, Pages 82-87

  Luszczki, Jarogniew J ^a,b   Wlaz, Aleksandra ^a   Marzeda, Ewa ^b   Durmowicz, Dariusz ^b   Florek Luszczki, Magdalena ^b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

6 Hz psychomotor seizure model; Antiepileptic drugs; Drug interactions; Isobolographic analysis; Lamotrigine; Levetiracetam

Indexed keywords

ETIRACETAM; LAMOTRIGINE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; ISOBOLOGRAPHY; MALE; MOUSE; NONHUMAN; SEIZURE;

EID: 84882785292     PISSN: 2084980X     EISSN: None     Source Type: Journal    
DOI: 10.12923/j.2084-980X/26.1/a.18     Document Type: Article

References (42)

1. Bar ton M.E. et al.: Pharmacological char acterization of the 6 Hz psy chomotorseizure model of par tial epilepsy. Epilepsy Res., 47, 217, 2001.
2. Che ung H., Kamp D., Har ris E.: An in vitro in ves ti gation of the action of lamotrig ine onneuronal voltage-activated so-dium channels. Epilepsy Res., 13, 107, 1992.
3. Deck ers C.L.P. et al.: Cur rent limitations of antie pilep tic drug ther apy: acon ferencereview. Epilepsy Res., 53, 1, 2003.
4. Do nato Di PaolaE. et al.: In fluence of leveti racetam onthe anticon vul sant efficacy of con ventional antie pilep tic drugs against au dio genic seizures in DBA/2 mice. Epilepsy Res., 75, 112, 2007.
5. Dudra-Jastrzebska M. et al.: Iso bo lo graphic char acteriza-tion of the anticon vul santinteraction profiles of leveti-racetam in com bination with clo nazepam, ethosuximide, pheno bar bital and val proate inthe mouse pentylenetetrazole-induced seizure model. Seizure, 18, 607, 2009.
6. Dudra-Jastrzebska M. et al.: Pharmaco dy namic and phar-macokineticinter action profiles of leveti racetam in com bi-nation with ga bap entin, ti aga bine and viga batrin inthe mouse pentylenetetrazole-induced seizure model: An iso-bo lo graphic analysis. Eur. J. Pharmacol., 605, 87, 2009.
7. EP 2 462 990 A1 (European Pat ent Application; https://data.epo.org/ publication-server/rest/v1.0/publication-dates/20120613/pat ents/EP2462990NWA1/ docu ment.pdf)
8. Gower A.J. et al.: Effects of leveti racetam, a novel antie pilep-tic drug, on con vul sant activityintwo genetic rat models of epilepsy. Epilepsy Res., 22, 207, 1995.
9. Gower A.J. et al.: Ucb L059, a novel anti-convulsant drug: pharmacological pro file in animals. Eur. J. Pharmacol., 222, 193, 1992.
10. Erratum pub lished in: Eur. J. Pharmacol., 230, 389, 1993.
11. Ka min ski R.M. et al.: Bene fits of com binationther apyin epi-lepsy: areview of pre clinical evi dence with leveti racetam. Epilep sia, 50, 387, 2009.
12. Klit gaard H. et al.: Evi dence for a unique pro file of leveti-racetam in ro dent models of seizures andepilepsy. Eur. J. Pharmacol., 353, 191, 1998.
13. Leach M.J., Mar den C.M., Miller A.A.: Pharmacological studies on lamotrig ine, a novel potential antie pilep tic drug: II. Neurochemical studies onthe mecha nism of action. Epi-lep sia, 27, 490, 1986.
14. Litchfield J.T., Wil coxon F.: A sim plified method of evalu at-ing dose-effect ex periments. J. Pharmacol. Exp. Ther., 96, 99, 1949.
15. Loewe S.: The prob lem of syn er gism and antago nism of com bined drugs. Arzne imit tel forschung, 3, 285, 1953.
16. Löscher W., Hönack D.: Pro file of ucb L059, a novel anticon-vul sant drug, in models of par tial and generalizedepilepsyin mice and rats. Eur. J. Pharmacol., 232, 147, 1993.
17. Luk y anetz E.A., Shkryl V.M., Kostyuk P.G.: Se lective block-ade of N-type cal cium channels by leveti racetam. Epilep sia, 43, 9, 2002.
18. Lynch B.A. et al.: The syn ap tic vesicle protein SV2A is the bind ing site for the antie pilep tic drug leveti racetam. Proc. Natl. Acad. Sci. USA, 101, 9861, 2004.
19. Uszczki J.J. et al.: Pharmaco dy namic and pharmacokinetic char acterization of inter actions between leveti racetam and nu merous antiepileptic drugs inthe mouse maximal electro-shock seizure model: an iso bo lo graphic analysis. Epilep sia, 47, 10, 2006.
20. Uszczki J.J. et al.: Leveti racetam se lectively potenti ates the acuteneurotoxic effects of topi ra mate and car ba mazepine intherotarod testin mice. Eur. Neurop sy chopharmacol., 15, 609, 2005.
21. Uszczki J.J. et al.: Leveti racetam and fel ba mate inter act both pharmaco dy namically and pharmacokinetically: an iso bo-lo graphic analysis inthe mouse maximal electroshock model. Epilep sia, 48, 806, 2007.
22. Uszczki J.J., Antkiewicz-Michaluk L., Czuczwar S.J.: Iso bo-lo graphic analysis of inter actions between 1-methyl-1,2,3,4-tetrahydroisoquinoline and four conventional antie pilep tic drugs inthe mouse maximal electroshock-induced seizure model. Eur. J. Pharmacol., 602, 298, 2009.
23. Uszczki J.J., Czuczwar S.J.: How significantis the difference between drug doses in fluencing thethreshold forelectro-con vul sions? Pharmacol. Rep., 57, 782, 2005.
24. Uszczki J.J., Czuczwar S.J.: Isobolo graphic profile of inter-actions betweenti aga bine and ga bap entin: apre clinical study. Naunyn-Schmiedebergs Arch. Pharmacol., 369, 434, 2004.
25. Uszczki J.J., Czuczwar S.J.: Preclinical pro file of com bina-tions of some second-generation antiepileptic drugs: an iso-bolo graphic analysis. Epilep sia, 45, 895, 2004.
26. Uszczki J.J. et al.: Iso bo lo graphic and behav ioral char acteri-zations of inter actions betweenviga batrin and ga bap entin intwo ex perimental models of epilepsy. Eur. J. Pharmacol., 595, 13, 2008.
27. Uszczki J.J. et al.: Iso bo lo graphic analysis of inter actions between lore clezole and conventional antiepileptic drugs inthe mouse maximal electroshock-induced seizure model. Naunyn-Schmiedebergs Arch. Pharmacol., 373, 169, 2006.
28. Uszczki J.J. et al.: Iso bo lo graphic char acterization of inter-action of leveti racetam with clo ba zam inthe mouse 6 Hz psychomotorseizure model. J. Pre-Clin. Clin. Res., 6, 25, 2012.
29. Madeja M. et al.: Re duction of voltage-operated potassium cur rents by leveti racetam: a novel antie pilep tic mecha nism of action? Neuropharmacology, 45, 661, 2003.
30. Marrosu F. et al.: Leveti racetam at tenu atessponta ne ousspike-and-wave dis charges in DBA/2J mice. Epilepsy Res., 75, 224, 2007.
31. Mazarati A.M. et al.: Anticon vul sant effects of leveti racetam and levetiracetam-diazepam com binations in experimental status epilep ticus. Epilepsy Res., 58, 167, 2004.
32. Nie spodzi any I., Klit gaard H., Mar gine anu D.G.: Leveti-racetam in hib its thehigh-voltage-activated Ca(2+) currentin py rami dal neurones of rat hippocam pal slices. Neurosci. Lett., 306, 5, 2001.
33. Palma E. et al.: GABA(A)-cu rrent run down of tem poral lobe epilepsyis associ ated with re petitive acti vation of GABA(A) "phasic" re cep tors. Proc. Natl. Acad. Sci. USA, 104, 20944, 2007.
34. Pat salos P.N.: Clinical pharmacokinetics of leveti racetam. Clin. Pharmacokinet., 43, 707, 2004.
35. Perucca E.: Pharmacological prin ciples as a basis for poly-ther apy. Acta Neurol. Scand. Suppl., 162, 31, 1995.
36. Rigo J.M. et al.: The anti-epileptic drug leveti racetam re-verses the in hibition by negativeallosteric modulators ofneuronal GABA-and glycine-gated cur rents. Br. J. Pharma-col., 136, 659, 2002.
37. Sills G.J. et al.: Pharmaco dy namicinter action studies with topi ra mate inthe pentylenetetra zoland maximal electro-shock seizure models. Seizure, 13, 287, 2004.
38. Ste fani A., Spa doni F., Bernardi G.: Voltage-activated cal-cium channels: tar gets of antie pilep tic drug ther apy? Epilep-sia, 38, 959, 1997.
39. Tal larida R.J. (2000). Drug syn er gism and dose-effect data analysis. Chap man & Hall/CRC, Boca Raton, USA.
40. Vino gra dova L.V., van Rijn C.M.: Anticon vul sive and antie-pilepto genic effects of leveti racetam inthe au dio genic kin-dling model. Epilepsia, 49, 1160, 2008.
41. Wo jda E. et al.: Iso bo lo graphic char acterization of inter ac-tions of leveti racetam with thevari ous antiepileptic drugs inthe mouse 6 Hz psy chomotorseizure model. Epilepsy Res., 86, 163, 2009.
42. Zona C. et al.: Levetiracetam does not modulateneuronal voltage-gated Na+ and T-type Ca2+ currents. Seizure, 10, 279, 2001.